Home » Xinhua Pharma: The production of new crown oral drugs needs further certification and signing of a contracted production agreement丨Company Q&A

Xinhua Pharma: The production of new crown oral drugs needs further certification and signing of a contracted production agreement丨Company Q&A

by admin
Xinhua Pharma: The production of new crown oral drugs needs further certification and signing of a contracted production agreement丨Company Q&A

Share to WeChat

Open WeChat, click “Discover” at the bottom,
Use “Scan” to share webpages to Moments.

First Financial 2022-07-26 12:53:35

Editor in charge: Hao Yunying

On July 25, the State Food and Drug Administration, in accordance with the relevant provisions of the Drug Administration Law, conducted emergency review and approval in accordance with the special drug approval procedures, and approved the application for registration of real biological azvudine tablets for the treatment of new coronavirus pneumonia with conditions. In April this year, Real Biology signed an agreement with Xinhua Pharma, agreeing that Xinhua Pharma will be the product manufacturer and distributor of Azvudine and other products it owns in China and other countries agreed by both parties. In the morning, the reporter called Xinhua Pharmaceuticals as an investor, and its investor hotline said that the framework agreement has indeed been signed, but the specific production still needs to apply for relevant documents and sign a more detailed production agreement.

Xinhua Pharma: The production of new crown oral drugs needs further certification and signing of a contracted production agreement丨Company Q&A

On July 25, the State Food and Drug Administration, in accordance with the relevant provisions of the Drug Administration Law, conducted emergency review and approval in accordance with the special drug approval procedures, and approved the application for registration of real biological azvudine tablets for the treatment of new coronavirus pneumonia with conditions. In April this year, Real Biology signed an agreement with Xinhua Pharma, agreeing that Xinhua Pharma will be the product manufacturer and distributor of Azvudine and other products it owns in China and other countries agreed by both parties. In the morning, the reporter called Xinhua Pharmaceuticals as an investor, and its investor hotline said that the framework agreement has indeed been signed, but the specific production still needs to apply for relevant documents and sign a more detailed production agreement.

This content is original by Yicai, and the copyright belongs to Yicai. Without the written authorization of CBN, it may not be used in any way, including reprinting, excerpting, copying or creating mirror images. Yicai.com reserves the right to pursue legal liability of infringers. For authorization, please contact Yicai Copyright Department: 021-22002972 or 021-22002335; [email protected].

See also  Netizens spontaneously "defend the snow lotus": a pack of 50 cents earns a few cents, and the true conscience fans have broken 500,000 in 4 days - Network Anecdote - cnBeta.COM

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy